Elsevier

Drug Discovery Today

Volume 27, Issue 7, July 2022, Pages 1785-1788
Drug Discovery Today

Drug repurposing: An effective strategy to accelerate contemporary drug discovery

https://doi.org/10.1016/j.drudis.2022.05.026Get rights and content

Cited by (0)

Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined the research group of Professor Xinyong Liu as a Lecturer (2010−2012). From 2012 to 2014, he worked as a postdoctoral fellow funded by JSPS (Japan Society for the Promotion of Science) in Japan. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel antiviral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches.

Bin Yu gained his Bachelor degree in Pharmaceutical Sciences (2010) from Zhengzhou University, China, where he also gain his Master degree in Pharmaceutical Engineering (2012). He then achieved his PhD study (2016) for work on chemistry driven drug discovery under the co-supervision of Prof. David Spring (University of Cambridge, UK) and Prof. Hong-Min Liu (Zhengzhou University). Since then, he joined the faculty at School of Pharmaceutical Sciences, Zhengzhou University and was then promoted to a Professorship of Medicinal Chemistry in 2020. His research interests mainly focus on new drug discovery for novel therapeutics. To date, he has published over 130 papers in international peer-reviewed journals. Number of citations (Google Scholar): 3535, H-index = 32, H10-index = 76. He also co-edited two books published by Elsevier and Springer Nature, respectively and filed 25 patents (10 of them licensed). During the last three years, he has been awarded several prestigious awards and granted several funds. He currently serves as the Faculty Member of Faculty Opinions (formerly known as F1000 Prime), associate editor of Frontiers in Drug Discovery, section editor of Current Medicinal Chemistry, review editor of Frontiers in Chemistry, editorial board member of Nature Reviews Drug Discovery (Chinese version), Acta Pharmaceutica Sinica B, Chinese Chemical Letters, and Chinese Journal of Natural Medicines as well as the managing guest editor of Drug Discovery Today, European Journal of Medicinal Chemistry, Pharmacological Research, Current Medicinal Chemistry, Frontiers in Pharmacology, Current Topics in Medicinal Chemistry and Chemical Biology & Drug Design.

Liang Ouyang received his PhD in medicinal chemistry from West China School of Pharmacy, Sichuan University, in 2010. He is now a professor at the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University. He has a longstanding interest in the design and synthesis of drugs based on original autophagy targets, the application of lead compound screening, the development of new drug target recognition methods and drug discovery, taking advantage of interdisciplinary approaches, including systems biology, structural biology, computer-aided drug design, medicinal chemistry, chemical biology, and molecular biology.

View Abstract